| |
|
Form Serial Number: |
CS20260703E00132 |
| 1.
Date of relevant event: |
29/06/2026
(dd/mm/yyyy)
|
| 2.
Date when the substantial shareholder becomes aware of the relevant event / interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
09637 |
| 4.
Name of listed corporation: |
Alebund Pharmaceuticals (Jiangsu) Ltd. - B - H Shares |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
227,122,189 |
| 7.
Name of substantial shareholder: |
LAV Asset Management (Hong Kong) Limited |
| 8.
Registered office: |
22nd Floor, Tai yau Building, 181 Johnston Road, Wan Chai, Hong Kong |
| 9.
Principal place of business in Hong Kong: |
Room 606, St George's Building, 2 Ice House Street, Central, Hong Kong |
| 15.
Exchange on which listed: |
|
| 16.
Name of listed parent and exchange on which parent is listed: |
|
|
| 17.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved |
Currency of transaction |
On Exchange
|
Off Exchange
|
| Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Nature of consideration
|
|
Long position |
| 1101 | The percentage level of your interest in the shares has increased because:
you purchased the shares |
|
|
|
450,000 |
HKD |
46.0000 |
45.0615 |
|
|
| Short position |
|
|
|
|
|
|
|
|
|
|
|
| 18.
Total shares immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 15,897,290 | 6.99 |
|
|
| 19.
Total shares immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 16,347,290 | 7.20 |
|
|
| 20.
Capacity in which interests disclosed in Box 19 are held: |
| Capacity code | Number of shares |
| |
|
|
|
|
| 21.
Further information in respect of derivative interests: |
| Derivatives code | Number of shares |
| | |
|
|
| 22.
Further information in relation to interests of corporations controlled by substantial shareholder: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
|
|
| 23.
Further information in relation to interests held by substantial shareholder jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
|
| 24.
Further information from a trustee, a beneficiary of a trust, or a person who set up a discretionary trust: |
| Names of trust | Address | Status code | Number of shares |
| | | |
|
|
| 25.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a substantial shareholder is interested under sections 317 and 318 | |
|
|
| 26.
Details of person(s) in accordance with whose directions the substantial shareholder or its directors are accustomed to act: |
| Names | Address | Relationship Code | Percentage (%) |
| | | |
|
| |
| 27.
Supplementary information: |
On June 29, 2026 (trade date), LAV Star Limited and LAV Star Opportunities Limited each purchased 200,000 H Shares of Alebund Pharmaceuticals (Jiangsu) Limited, while LAV Public Equity Master Fund purchased 50,000 H Shares. The settlement date for all transactions is July 2, 2026.
|
| 28.
Log/Serial Number of the previous form: |
|
| 29.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 2: |
03/07/2026
(dd/mm/yyyy)
|
|
|
|
|